Hereditary form of parkinsonism-dementia

Annals of Neurology

Volumn 43, Issue 6, 1998, Pages 768-781

  Muenter, Manfred D ^a   Forno, Lysia S ^b   Hornykiewicz, Oleh ^c   Kish, Stephen J ^d   Maraganore, Demetrius M ^f   Caselli, Richard J ^a   Okazaki, Haruo ^f   Howard Jr , Frank M ^a   Snow, Barry J ^g   Calne, Donald B ^e  

^a MAYO CLINIC   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^f MAYO CLINIC   (United States)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FAMILY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INHERITANCE; LEWY BODY; MALE; PARKINSON DISEASE; PEDIGREE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ADULT; ANTIPARKINSON AGENTS; CHOLINE O-ACETYLTRANSFERASE; DEMENTIA; DOPAMINE; FAMILY HEALTH; FEMALE; GENES, DOMINANT; HIPPOCAMPUS; HOMOVANILLIC ACID; HUMANS; LEVODOPA; LEWY BODIES; LOCUS COERULEUS; MALE; MIDDLE AGED; NEOSTRIATUM; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PEDIGREE; SUBSTANTIA INNOMINATA; SUBSTANTIA NIGRA; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 15144345616     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430612     Document Type: Article

References (70)

1. Leroux P-D. Contribution à l'étude des causes de la paralysie agitante. Thesis, Paris, 1880
2. Lhirondel G. Antécédents et causes dans la maladie de Parkinson. Thesis, Paris, 1883
3. Borgherini A. Della paralisi agitante; studio clinico. Riv sper di freniat 1889-1890;15:1-49
4. Clerici M. La malattia di Parkinson e l'eredo-familiarita. Estratto dal Bolletino clinico-scientifico della Poliambulanza di Milano, 1899. Rev Neurol 1899;7:495-496
5. Collins J, Muskens LJJ. A clinical study of twenty-four cases of paralysis agitans, with remarks on the treatment of the disease. N Y Med J 1899;70:41-46
6. Berger O. Paralysis agitans. 1882. Zit nach Günther: über paralysis agitans. Dtsch Z Nervenheilk 1913;47:192-206
7. Lundborg H. Medizinisch-biologische Familienforschungen innerhalb eines 2232köpfigen Bauerngeschlechtes in Schweden (Provinz Bleckinge). Jena 1913, zit nach Mjönes H. Acta Psychiatr Scand Suppl 1949;54:1-195
8. Benedek L, Csörsz K. Heredofamiliarität bei paralysis agitans. Dtsch Z Nervenheilk 1923;79:368-373
9. Bell J, Clark AJ. A pedigree of paralysis agitans. Ann Eugenics 1925-1926;1:455-462
10. Mjönes H. Paralysis agitans: clinical and genetic study. Acta Psychiatr Neurol Scand Suppl 1949;54:1-195
11. Branger F. Die familiäre Form der paralysis agitans. Ein Stammbaum aus Graubünden. Inaugural dissertation, Zürich, 1953
12. Branger F. Une forme familiale de paralysie agitante dans une souche des Grisons. J Genet Hum 1956;5:261-270
13. Otto FG. Ein Beitrag zu familiär gehäuft auftretenden Fällen von Parkinsonismus. Nervenarzt 1983;54:423-425
14. Günther H. Ueber paralysis agitans. Dtsch Z Nervenh 1913; 47:192-206
15. Kückens H. Über heredofamiliarität bei paralysis agitans. Klin Wochenschr 1925;4:2289-2291
16. Wrede J. Über hereditären Parkinsonismus. Arch Psychiatr 1936;104:597-610
17. Kehrer F. Der Ursachenkreis des Parkinsonismus (Erblichkeit, Trauma, Syphilis). Arch Psychiatr 1930;91:187-268
18. Scarpalézos S. Sur la notion d'hérédité similaire dans la maladie de Parkinson; données statistiques sur 626 cas d'états parkinsoniens. Rev Neurol 1948;80:184-203
19. Pescetto G. Nuovi aspetti dell'ereditarietà nel morbo di Parkinson. Riv Neurobiol 1957;4:611-614
20. Golbe LI, Di Iorio G, Bonavita V, et al. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990;27: 276-282
21. Siegfried J. Die Parkinsonsche Krankheit und ihre Behandlung. New York: Springer-Verlag, 1968
22. Allan W. Inheritance of shaking palsy. Arch Intern Med 1937; 60:424-436
23. Spellman GG. Report of familial cases of parkinsonism: evidence of a dominant trait in a patient's family. JAMA 1962; 179:372-374
24. Sage JI, Miller DC, Golbe LI, et al. Clinically atypical expression of pathologically typical Lewy-body parkinsonism. Clin Neuropharmacol 1990;13:36-47
25. Maraganore DM, Harding AE, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord 1991; 6:205-211
26. Burn DJ, Mark MH, Playford ED, et al. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992;42:1894-1900
27. Duvoisin RC, Johnson WG. Hereditary Lewy-body parkinsonism and evidence for a genetic etiology of Parkinson's disease. Brain Pathol 1992;2:309-320
28. Wszolek ZK, Cordes M, Calne DB, et al. Hereditarer Morbus Parkinson: bericht über drei Familien mit autosomal-dominantem Erbgang. Nervenarzt 1993;64:331-335
29. Mizutani T, Inose T, Nakajima S, Gambetti P. Familial parkinsonism and dementia with "ballooned neurons." Adv Neurol 1993;60:613-617
30. Waters CH, Miller CA. Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 1994;35: 59-64
31. Golbe LI, Lazzarini AM, Schwarz KO, et al. Autosomal dominant parkinsonism with benign course and typical Lewy-body pathology. Neurology 1993;43:2222-2227
32. Wszolek ZK, Pfeiffer B, Fulgham JR, et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 1995;45:502-505
33. Markopoulou K, Wszolek ZK, Pfeiffer RF. A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol 1995;38:373-378
34. Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996;40:767-775
35. Muenter MD, Howard FM Jr, Okasaki H, et al. A familial Parkinson-dementia syndrome. Neurology 1986;36(suppl 1): 115 (Abstract)
36. Sutton JP, Pulst S-M. Familial parkinsonism in a kindred of Portuguese descent: absence of known markers for Machado-Joseph disease. Neurology 1996;46:A386 (Abstract)
37. Rossi P, Albanese A, Montini L, et al. A clinical-genetic study of familial Parkinson's disease in Italy. Mov Disord 1996; 11(suppl 1):143 (Abstract)
38. Martin WR, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989;26:535-542
39. Sossi V, Buckley KR, Snow BJ, et al. Recovery of the human striatal signal in a slice oriented positron emission tomograph. J Nucl Med 1993;34:481-487
40. Sternberger LA. Immunocytochemistiy. 3rd ed. New York: John Wiley, 1986
41. Forno LS, Murphy GM, Eng LF. Immunocytochemical study of Lewy bodies in sympathetic ganglia. Neurodegeneration 1992;1:135-144
42. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880
43. Felice LJ, Felice JD, Kissinger PT. Determination of catecholamines in rat brain parts by reverse-phase ion pair liquid chromatography. J Neurochem 1978;31:1461-1465
44. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 1975;24:407-409
45. Heaton RK. Wisconsin Card Sorting Test manual. Odessa, FL: Psychological Testing Resources, 1981
46. Wechsler D. Wechsler Memory Scale Revised. San Antonio, TX: The Psychological Corporation, 1987
47. Benton AL, Hamsher KDS. Multilingual Aphasia Examination. Iowa City, IA: University of Iowa, 1976
48. Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. Mayo Clin Proc 1987;62:281-288
49. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330
50. Lorente de Nó R. Studies on the structure of the cerebral cortex. Continuation of the study of the ammonic system. J Psychol Neurol 1934;46:113-177
51. Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961;20:237-244
52. Dickson DW, Schmidt ML, Lee VM, et al. Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol (Berl) 1994;87:269-276
53. Kim H, Gearing M, Mirra SS. Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies. Neurology 1995;45:1768-1770
54. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455
55. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 1993;60:140-147
56. Graff-Radford NR, Damasio AR, Hyman BT, et al. Progressive aphasia in a patient with Pick's disease: a neuropsychological, radiologie, and anatomic study. Neurology 1990;40:620-626
57. Tranel D, Damasio AR. Dissociated verbal and nonverbal retrieval and learning, following left anterior temporal damage. J Clin Exp Neuropsychol 1988;10:17 (Abstract)
58. Caselli RJ, Ivnik RJ, Duffy JR. Associative anomia: dissociating words and their definitions. Mayo Clin Proc 1991;66:783-791
59. Zola-Morgan S, Squire LR, Amaral DG. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 1986;6:2950-2967
60. Rossor MN, Garrett NJ, Johnson AL, et al. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 1982;105:313-330
61. Perry RH, Tomlinson BE, Candy JM, et al. Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet 1983;2:789-790 (Letter)
62. Ruberg M, Ploska A, Javoy-Agid F, Agid Y. Muscarinic binding and choline acetyltransferase activity in parkinsonian subjects with reference to dementia. Brain Res 1982;232:129-139
63. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992;268:2523-2529
64. Rogers SL, Doody R, Mohs R, Friedhoff LT. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial. Neurology 1996;46:A217 (Abstract)
65. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442
66. Muenter MD, Tyce GM. L-dopa therapy of parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239
67. Muenter MD. Should levodopa therapy be started early or late? Can J Neurol Sci 1984;11(suppl):195-199
68. Lavin PJ, Bone I, Sheridan P. Studies of hypothalamic function in Huntington's chorea. J Neurol Neurosurg Psychiatry 1981; 44:414-418
69. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43: 1173-1180
70. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047